CN100369899C - 具有抗癌活性的取代的吲唑 - Google Patents

具有抗癌活性的取代的吲唑 Download PDF

Info

Publication number
CN100369899C
CN100369899C CNB038058731A CN03805873A CN100369899C CN 100369899 C CN100369899 C CN 100369899C CN B038058731 A CNB038058731 A CN B038058731A CN 03805873 A CN03805873 A CN 03805873A CN 100369899 C CN100369899 C CN 100369899C
Authority
CN
China
Prior art keywords
indazole
benzsulfamide
phenyl
methyl sulphonyl
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038058731A
Other languages
English (en)
Chinese (zh)
Other versions
CN1642922A (zh
Inventor
D·达穆尔
J-C·卡里
P·内梅切克
C·泰里耶
F·纳尔迪
B·菲洛什
M-P·谢里耶
D·贝扎尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN1642922A publication Critical patent/CN1642922A/zh
Application granted granted Critical
Publication of CN100369899C publication Critical patent/CN100369899C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
CNB038058731A 2002-03-11 2003-03-07 具有抗癌活性的取代的吲唑 Expired - Fee Related CN100369899C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/02996 2002-03-11
FR0202996A FR2836914B1 (fr) 2002-03-11 2002-03-11 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Publications (2)

Publication Number Publication Date
CN1642922A CN1642922A (zh) 2005-07-20
CN100369899C true CN100369899C (zh) 2008-02-20

Family

ID=27763684

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038058731A Expired - Fee Related CN100369899C (zh) 2002-03-11 2003-03-07 具有抗癌活性的取代的吲唑

Country Status (29)

Country Link
US (2) US6858638B2 (enExample)
EP (1) EP1487803A1 (enExample)
JP (1) JP4643910B2 (enExample)
KR (1) KR20040091128A (enExample)
CN (1) CN100369899C (enExample)
AR (1) AR038914A1 (enExample)
AU (1) AU2003242808B2 (enExample)
BR (1) BR0308339A (enExample)
CA (1) CA2478540A1 (enExample)
EC (1) ECSP045286A (enExample)
FR (1) FR2836914B1 (enExample)
GT (1) GT200300031A (enExample)
HN (1) HN2003000094A (enExample)
HR (1) HRP20040825A2 (enExample)
IL (2) IL163805A0 (enExample)
MA (1) MA27176A1 (enExample)
MX (1) MXPA04008446A (enExample)
NO (1) NO20044261L (enExample)
OA (1) OA12784A (enExample)
PA (1) PA8566701A1 (enExample)
PE (1) PE20040071A1 (enExample)
PL (1) PL372389A1 (enExample)
RU (1) RU2004130280A (enExample)
SV (1) SV2003001493A (enExample)
TN (1) TNSN04175A1 (enExample)
TW (1) TW200303863A (enExample)
UY (1) UY27712A1 (enExample)
WO (1) WO2003078402A1 (enExample)
ZA (1) ZA200406730B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247361A (zh) * 2010-05-20 2011-11-23 中国医学科学院药物研究所 5-硝基-1氢-吲唑-3-腈在制备药物中的应用

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
FR2864084B1 (fr) * 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
BRPI0515931A (pt) * 2004-09-29 2008-08-12 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
CN101243051A (zh) * 2005-08-25 2008-08-13 霍夫曼-拉罗奇有限公司 p38 MAP激酶抑制剂及使用它的方法
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007089646A1 (en) 2006-01-31 2007-08-09 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
JP5364875B2 (ja) * 2007-07-16 2013-12-11 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬としてのインダゾール類、ベンゾイソオキサゾール類およびベンゾイソチアゾール類
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2546294T7 (es) * 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN107108556B (zh) 2014-11-03 2020-09-29 艾欧米制药有限公司 药用化合物
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US11926596B2 (en) 2017-07-21 2024-03-12 Kadmon Corporation, Llc Inhibitors of Rho associated coiled-coil containing protein kinase
WO2019046467A1 (en) 2017-08-29 2019-03-07 Rutgers, The State University Of New Jersey INDAZOLES THERAPEUTIC
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
JP2025504415A (ja) * 2022-01-12 2025-02-12 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物
EP4488275A4 (en) 2022-03-04 2025-07-23 Shanghai Yingli Pharm Co Ltd COMPOUND CONTAINING A FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途
CN119997982A (zh) 2022-09-09 2025-05-13 迈里克斯制药有限公司 包含nmt抑制剂的抗体药物偶联物及其用途
JP2026502949A (ja) 2022-12-30 2026-01-27 アヴィセンナ バイオサイエンシズ インコーポレイテッド アザインドールｒｏｃｋ阻害剤
WO2024254990A1 (zh) 2023-06-16 2024-12-19 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
AU2024392169A1 (en) * 2023-11-28 2026-06-11 Quantx Biosciences Us, Inc. Bicyclic heteroaryl compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6225747A (ja) * 1985-07-26 1987-02-03 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
WO1998005315A1 (en) * 1996-07-19 1998-02-12 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
WO1999064004A1 (en) * 1998-06-08 1999-12-16 Bristol-Myers Squibb Company QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE
WO2000073264A1 (en) * 1999-05-28 2000-12-07 Abbott Laboratories Cell proliferation inhibitors
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS514505Y2 (enExample) 1971-02-13 1976-02-07
NZ331941A (en) 1996-02-22 2000-04-28 Tularik Inc Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU1818400A (en) 1998-11-12 2000-05-29 Eli Lilly And Company Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
WO2002083648A1 (fr) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6225747A (ja) * 1985-07-26 1987-02-03 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
WO1998005315A1 (en) * 1996-07-19 1998-02-12 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
WO1999064004A1 (en) * 1998-06-08 1999-12-16 Bristol-Myers Squibb Company QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE
WO2000073264A1 (en) * 1999-05-28 2000-12-07 Abbott Laboratories Cell proliferation inhibitors
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247361A (zh) * 2010-05-20 2011-11-23 中国医学科学院药物研究所 5-硝基-1氢-吲唑-3-腈在制备药物中的应用
CN102247361B (zh) * 2010-05-20 2015-04-29 中国医学科学院药物研究所 5-硝基-1氢-吲唑-3-腈在制备药物中的应用

Also Published As

Publication number Publication date
IL163805A0 (en) 2005-12-18
PE20040071A1 (es) 2004-02-13
AR038914A1 (es) 2005-02-02
US20040106667A1 (en) 2004-06-03
US7473701B2 (en) 2009-01-06
JP2005533004A (ja) 2005-11-04
ECSP045286A (es) 2004-10-26
JP4643910B2 (ja) 2011-03-02
CA2478540A1 (fr) 2003-09-25
SV2003001493A (es) 2003-07-10
US20050059722A1 (en) 2005-03-17
UY27712A1 (es) 2003-09-30
HN2003000094A (es) 2003-12-15
AU2003242808A1 (en) 2003-09-29
HRP20040825A2 (en) 2005-06-30
BR0308339A (pt) 2005-02-01
MA27176A1 (fr) 2005-01-03
KR20040091128A (ko) 2004-10-27
WO2003078402A1 (fr) 2003-09-25
FR2836914B1 (fr) 2008-03-14
TNSN04175A1 (fr) 2007-03-12
US6858638B2 (en) 2005-02-22
PA8566701A1 (es) 2003-12-10
NO20044261L (no) 2004-11-25
FR2836914A1 (fr) 2003-09-12
ZA200406730B (en) 2005-08-24
CN1642922A (zh) 2005-07-20
GT200300031A (es) 2006-05-26
PL372389A1 (en) 2005-07-25
MXPA04008446A (es) 2004-12-06
EP1487803A1 (fr) 2004-12-22
TW200303863A (en) 2003-09-16
AU2003242808B2 (en) 2008-09-18
IL163805A (en) 2009-08-03
RU2004130280A (ru) 2005-06-27
OA12784A (fr) 2006-07-10

Similar Documents

Publication Publication Date Title
JP4643910B2 (ja) 抗癌活性を有する置換インダゾール
JP5676650B2 (ja) プロテインキナーゼ阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
AU2005259139B2 (en) Substituted indazoles, compositions containing same, preparation and use
JP7337951B2 (ja) 癌を治療するための窒素含有芳香族ヘテロ環アミド誘導体
JP4253188B2 (ja) 血管新生制御剤としてのピリミジンアミン
KR100928602B1 (ko) 티로신 키나제 억제제로서 적합한 시클릭 디아릴 우레아
JP2005529954A (ja) 化学プロセス
US20100016307A1 (en) Novel compounds
EP4085055A1 (en) Aminopyrimidine compounds
CN107021937B (zh) 苯并噻唑甲酰胺类化合物及其应用
JP2005501826A (ja) 置換イソインドールおよびそれらの使用
CA3136535A1 (en) Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2004111036A1 (en) 4- (heterocyclyl- fused phenyl)- 3- (phenyl or pyrid -2- yl) pyrazoles as inhibitors of the alk-5- receptor
KR20070113214A (ko) 히드라지노카르보닐-티에노[2,3-ｃ]피라졸, 제조 방법,그를 함유하는 조성물 및 용도
WO2023031308A1 (en) Ccr2 inhibitors
JP2007511571A (ja) 癌およびアテローム性動脈硬化症のような疾患の治療において有用な置換イソキノリン
KR100744826B1 (ko) 이미다졸기가 치환된 퀴놀리논 유도체
HK1142592A1 (en) Alkynylpyrimidines as tie2 kinase inhibitors
HK1142592B (en) Alkynylpyrimidines as tie2 kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075249

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075249

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080220

Termination date: 20110307